After 20 days of treatment, the percentage of central memory T cells (CD44+CD62L+) among the CD8+ T subset and the CD4+ T subset in the tumor from mice was significantly higher than that of the PBS group, with 17.4% and 31.6%, respectively (Fig. 6H and I). The gene discussed is SELL; the disease is neoplasm.